Company profile
Luye Pharma Group
Public Market Listing
2186HKEX
Live quotes, historical charts, and market capitalization for Luye Pharma Group are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(9 total)
9Total Assets
2Approved
3Phase 3 / Filed
4Phase 1–2 / Early
5Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Paliperidone palmitate (Erzofri)(Erzofri) | Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | Schizophrenia |
Risperidone (Rykindo)(Rykindo) | Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | Schizophrenia |
Ansofaxine hydrochlorideNo recent activity | Phase 3 | Serotonin/norepinephrine/dopamine transporterSmall molecule | Major Depressive Disorder |
LY01008No recent activity | Phase 3 | VEGF-AMonoclonal antibody | Non-Small Cell Lung Cancer |
LY03003No recent activity | Phase 3 | dopamineSmall molecule | Parkinson's Disease |
| Phase 2 | 5-HT2C/TAAR1 receptorSmall molecule | Alzheimer's DiseaseSchizophrenia | |
LY03009No recent activity | Phase 1 | dopamineSmall molecule | Parkinson's Disease |
| Phase 1 | Serotonin 5-HT2A receptor (antagonist / inverse agonist) · 5-HT2A/5-HT2C · 5-HT2A/2C receptorSmall molecule | Alzheimer's DiseaseParkinson's DiseaseSchizophrenia | |
| Phase 1 | Norepinephrine/dopamine transporter + GABA-A receptorSmall molecule | Major Depressive Disorder |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.